Oxidative status and malondialdehyde in beta-thalassaemia patients.
BACKGROUND
In beta-thalassaemia syndromes, decreased or impaired biosynthesis of beta-globin leads to accumulation of unpaired alpha-globin chains. Moreover, the iron overload in beta-thalassaemia patients generates oxygen-free radicals and peroxidative tissue injury. The aim of this study was to detect and correlate iron overload parameters with the oxidative stress and the antioxidant capability in beta-thalassaemia patients.


METHODS
Serum iron, transferrin saturation, serum ferritin, nontransferrin-bound iron (NTBI), levels of serum free and total (free + bound) malondialdehyde (MDA) and total peroxyl radical-trapping antioxidant parameter (TRAP) were evaluated in 21 regularly transfused beta-thalassaemia major (TM) patients, 13 untransfused beta-thalassaemia intermedia (TI) patients and 17 healthy controls. Blood from the TM patients was drawn 48 h after the last desferoxamine (20-40 mg kg(-1)) infusion and just before transfusion.


RESULTS
Free and total MDA and NTBI levels were higher in the TM patients than in the TI. In the TM patients the free MDA levels correlated positively with serum iron (r = +0.3, P = 0.0006), whereas the total MDA correlated positively with NTBI (r = +0.45, P = 0.037). However, a negative correlation was observed between TRAP and NTBI (r = -0.4, P = 0.0006). In the TI patients there was no significant correlation between free or total MDA and TRAP or NTBI.


CONCLUSIONS
Our results confirm the peroxidative status generated by iron overload in thalassaemia patients and highlight the rapid formation of marked amounts of free MDA despite the chelation therapy in TM patients.
Cighetti
Giuliana
G
Department of Medical Chemistry and Biochemistry, Ospedale Maggiore IRCCS, Faculty of Medicine, University of Milan, Via Saldini 50, 20133 Milan, Italy. giuliana.cighetti@unimi.it
Duca
L
L
Bortone
L
L
Sala
S
S
Nava
I
I
Fiorelli
G
G
Cappellini
M D
MD
D000328:Adult; D000975:Antioxidants / Q000378:metabolism; D005260:Female; D006801:Humans; D007501:Iron / Q000097:blood*; D007502:Iron Chelating Agents / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology*; D010545:Peroxides / Q000378:metabolism; D014168:Transferrin / Q000378:metabolism; D017086:beta-Thalassemia / Q000378:metabolism*
D000975:Antioxidants; D007502:Iron Chelating Agents; D010545:Peroxides; D014168:Transferrin; D008315:Malondialdehyde; D007501:Iron